Payment overview · 2025
General Payments
$953.07
48 reported records · 15 companies
Healthcare provider profile · identity verified
Patrick M Lowden, MD
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1770527657
Verified facts
What the public records show
CMS Open Payments records show Patrick M Lowden, MD received $953.07 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Paxlovid, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $213.02 | 22.4% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.60 | 15.9% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $151.49 | 15.9% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $84.76 | 8.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $59.61 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.89 | 6.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.91 | 5.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.53 | 4.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.19 | 2.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.83 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.24 | 2.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.38 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.33 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.51 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $908.07 | 47 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $213.02 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.97 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.82 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $84.76 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $74.75 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $59.61 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.91 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 204 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 203 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
203 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
203 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1259 | 358 |
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 565 | 158 |
| Losartan Potassium | Losartan Potassium | 388 | 107 |
| Lisinopril | Lisinopril | 385 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 322 | 90 |
| Omeprazole | Omeprazole | 297 | 85 |
| Gabapentin | Gabapentin | 293 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 69 |
| Alprazolam | Alprazolam | 234 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 61 |
| Metformin Hcl | Metformin Hcl | 217 | 65 |
| Eliquis | Apixaban | 204 | 39 |
| Jardiance | Empagliflozin | 203 | 45 |
| Simvastatin | Simvastatin | 194 | 51 |
| Lorazepam | Lorazepam | 190 | 49 |
| Metformin Hcl Er | Metformin Hcl | 190 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 53 |
| Carvedilol | Carvedilol | 182 | 46 |
| Sertraline Hcl | Sertraline Hcl | 178 | 54 |
| Allopurinol | Allopurinol | 175 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 67 |
| Trazodone Hcl | Trazodone Hcl | 154 | 40 |
| Valsartan | Valsartan | 152 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 30 |
| Atenolol | Atenolol | 141 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 23 |
| Prednisone | Prednisone | 120 | 74 |
| Furosemide | Furosemide | 118 | 37 |
| Tramadol Hcl | Tramadol Hcl | 105 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 30 |
| Montelukast Sodium | Montelukast Sodium | 102 | 26 |
| Potassium Chloride | Potassium Chloride | 100 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 65 |
| Famotidine | Famotidine | 84 | 30 |
| Alendronate Sodium | Alendronate Sodium | 83 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 25 |
| Meloxicam | Meloxicam | 74 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 16 |
| Ezetimibe | Ezetimibe | 70 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 20 |
| Irbesartan | Irbesartan | 65 | 17 |
| Spironolactone | Spironolactone | 62 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 55 |
| Synthroid | Levothyroxine Sodium | 59 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 12 |
| Glimepiride | Glimepiride | 57 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 29 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 17 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 14 |
| Baclofen | Baclofen | 50 | 15 |
| Bumetanide | Bumetanide | 50 | suppressed |
| Celecoxib | Celecoxib | 50 | 12 |
| Ozempic | Semaglutide | 50 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 19 |
| Naproxen | Naproxen | 48 | 18 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Loperamide | Loperamide Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | suppressed |
| Finasteride | Finasteride | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 12 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Temazepam | Temazepam | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Felodipine Er | Felodipine | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 15 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 16 |
| Ibu | Ibuprofen | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 11 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Diazepam | Diazepam | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $953.07 · 48 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, EVENITY, GARDASIL 9, INSPIRE, JARDIANCE, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, ZAVZPRET, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error